



AETNA BETTER HEALTH® OF KENTUCKY

Pharmacy & Therapeutics Committee

2020 Second Quarter Meeting

Date: April 28, 2020
Location: WebEx/Call-in Only due to COVID-19
1-844-712-3250 Access Code 714 808 328
Facilitators: Stephanie Whyte, MD, Deputy CMO
April Cox, PharmD, Pharmacy Director

Committee Members			
April Cox, PharmD, Pharmacy Director		David Chand, MD, Medical Director	
Ted Cummings, R.Ph., Sr. Director of Pharmacy		Kelly Gannon, Director Clinical Health Services	
Stephanie Whyte, MD, Deputy Chief Medical Officer		Mamata Majmundar, MD, Medical Director	
Avril Anthony-Wilson, MD, Medical Director		LaVeda Gipson, PharmD, PMMP Clinical Pharmacist	
Avril Anthony-Wilson, MD, Medical Director		Lori Shook, MD, Medical Director	

Meeting Agenda

Topic	Facilitator
Attendance/Introductions (as applicable)	Whyte, S.
February 18, 2020 Meeting Minutes Approval	Cox, A.



Topic	Facilitator
<p>1. New Drug Reviews</p> <ul style="list-style-type: none">Fetroja injZerviate dropVyepti injNexletol tabSarclisa solUbrelyv tabCaplyta capTepezza injXpovio tabTazverikReyvow tab	<p>Cox, A.</p>

Topic	Facilitator
<p>2. Formulary Changes</p> <p><u>Generics Added in Previous Quarter</u></p> <p>Nevirapine susp Budesonide/Formoterol Aer Pyrimethamine tab 25mg</p> <p><u>Generics Not Added in Previous Quarter</u></p> <p>Penicillamine tab 250mg Doxepin tab 3 & 6mg Hydrocodone Bitartrate cap ER 12hr abuse deterrent Treprostinil Inj sln Carboprost tro inj 250mcg Amphetamine ER susp 1.25mg/mL Ciprofloxacin/Fluocinolone otic sln Sulconazole cream 1% Simvastatin sus 20mg/5mL Moxifloxacin opth sln 0.5% Irinotecan inj 300/15mL Phenobarbital inj 65mg/mL Ketorolac Tromethamine Nasal Spray Naproxen-Esomeprazole tab Azelastine/Fluticasone spr Ziprasidone Mesyl inj 20mg Diazoxide sus 50mg/mL Thiotepa inj Esomeprazole granule dr Everolimus tab 0.25, 0.5, 0.75mg</p> <p><u>New Biosimilars Not Added in Previous Quarter</u></p> <p>Zirabev Inj Ruxience Inj Trazimera Inj</p>	<p>Cox, A.</p>

3. Drug Class Reviews

No Changes

- Antiarrhythmics
- Antihemophilic
- Older Antidiabetics
- BPH
- Ophthalmic Antihistamines
- Weight Loss
- Gout
- Hepatitis B
- Hepatitis C
- Herpes
- EGRF Inhibitors for NSCLC
- Prenatal Vitamins
- Movement Disorder
- Opioids
- Hyperparathyroid
- Pediatric Multivitamins
- Enzyme Inhibitors for CML
- Smoking Deterrents
- ADHD
- Topical Anesthetics
- Interferons
- Muscle Relaxers
- Immunomodulators for MM
- Penicillins

With Changes

- Antiretrovirals
- Acne & Rosacea
- Androgens
- Antimalarials
- Chronic Constipation
- CDK4-6 Inhibitors
- Estrogens
- NSAIDs
- Opioid Partial Agonist
- Parkinson's
- PARP Inhibitors
- Topical Antifungal
- Topical NSAIDs

Cox, A.



Topic	Facilitator
Topical Antineoplastic Topical Corticosteroids Urinary Anti-infectives Urinary Antispasmodics <i>With UM Changes Only</i> Medication Assisted Treatment Contraceptives Otic agents Scabies Pediculicide Thyroid	
4. Formulary Update Summary Trelegy Irritable Bowel Syndrome Proton Pump Inhibitors	Cox, A.

5. Annual Guideline Reviews

No Changes

Acamprosate
Buprenorphine
Calcipotriene
Celecoxib
Elmiron
Erythromycin
Ondansetron Oral Soln
Quantity Level Limits
Spinraza
Vivitrol

With Changes

Atypical Antipsychotic
Brand Name Medications
Calcitonin Gene Related (CGRP) Receptor
Antagonists
Capecitabine
Chantix
Cinacalcet
Colony Stimulating Factors
Daraprim
Hemophilia
Hepatitis C
HIV medications
Imatinib
Inlyta
Interferons
Lidocaine Patch
Lyrica
Nexavar
Non-formulary medications
Onychomycosis
Opioids
Constipation agents
Promacta
Proton Pump Inhibitors
Pulmonary Arterial Hypertension
Revlimid
Second-Third Generation TKI

Cox, A.



Topic	Facilitator
Step Therapy Sutent Tadalafil Tarceva Testosterone agents Transmucosal Immediate Release Fentanyl Tykerb Votrient Weight Reduction Medications	
6. New Guideline Reviews Oxbryta	Cox, A.
Adjournment	Whyte, S.
Future Meeting Dates: 3Q2020: July 28, 2020 4Q2020: October 27, 2020	